NEWS
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of enrollment in its SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. The trial compared a triplet regimen (tamibarotene, venetoclax, and azacitidine) to a doublet regimen (venetoclax and azacitidine) in newly diagnosed, unfit AML patients with RARA gene overexpression.
The decision was based on a prespecified interim analysis of 51 patients, which showed similar complete response rates in both arms (65% triplet vs. 70% doublet). No new safety concerns were identified. Syros will present the trial data at the SOHO Annual Meeting in September 2024.
Despite this setback, Syros remains committed to evaluating tamibarotene in combination with azacitidine for higher-risk myelodysplastic syndrome (MDS) in the ongoing SELECT-MDS-1 Phase 3 trial, with pivotal data expected by mid-fourth quarter 2024.
The decision was based on a prespecified interim analysis of 51 patients, which showed similar complete response rates in both arms (65% triplet vs. 70% doublet). No new safety concerns were identified. Syros will present the trial data at the SOHO Annual Meeting in September 2024.
Despite this setback, Syros remains committed to evaluating tamibarotene in combination with azacitidine for higher-risk myelodysplastic syndrome (MDS) in the ongoing SELECT-MDS-1 Phase 3 trial, with pivotal data expected by mid-fourth quarter 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1664Followers
92Following
13KVisitors
Follow